Several scores and indexes have been validated to detect advanced hepatic fibrosis in patients with NAFLD, such as the alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ratio, the AST-to-platelet ratio index (APRI), and the Fibrosis-4 Index (FIB-4) [27,28,29,30], and innovative biomarkers have been proposed in patients with obesity [31]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.